ASH 2022 | Current approaches to GvHD prophylaxis and treatment

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Duran I Reynals Hospital, Barcelona, Spain, discusses current approaches to graft-versus-host disease (GvHD) prophylaxis and treatment in patients undergoing allogeneic stem cell transplantation (alloSCT). GvHD is a very important complication to address, and Dr Sureda highlights the high efficacy of post-transplant cyclophosphamide as a prophylactic strategy. While most first-line treatment strategies for GvHD are based on corticosteroids, novel agents such as ruxolitinib are valuable in patients refractory to corticosteroids, and Dr Sureda comments on the need to further improve treatment options for patients in the future. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.